Real-World Data

Analysing the impact of the FreeStyle Libre 2 Portfolio on the lives of real users

real world data

Outcomes for people with diabetes

The FreeStyle Libre 2 Portfolio is making a real impact on outcomes for people with diabetes.

Increases Time in Range1

Improves quality of life2

Reduces hypoglycaemia1,3

Decreases HbA1c4

Real-World Data

More frequent use of the FreeStyle Libre 2 systems* increases Time in Range5

Comparing two groups from lowest to highest scan rate8, patients who scanned more frequently using the FreeStyle Libre systems* spent 43% more Time In Range.

5.8 million

FreeStyle Libre 2 sensors

1.71 billion

hours of glucose readings


more Time In Range

(70-180 mg/dL) from 11.7 to 16.8 hours per day5 (p<0.001)

Frequent use of the FreeStyle Libre 2 system also resulted in patients spending 26% less Time Below Range (<54 mg/dL)5

The FreeStyle Libre 2 system is clinically proven to significantly reduce hypoglycaemia in T1D1 and T2D3 patients

Increased testing frequency is sustained over time with the FreeStyle Libre 2 system.9

Impact Study1: T1D Patients

Hypoglycaemia is defined as <70 mg/dL.

Replace Study3: T2D Patients

Clinical Evidence

Clinical benefits for a broad range of T1D and
T2D patients.

References & Disclaimers

Images are for illustrative purposes only. Not real patient, data or healthcare professional.

* FreeStyle Libre systems refers to the FreeStyle Libre 2 system

1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

2. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.

3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.

4. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178-1184. 2020;43(2):389-397.

5. Lang J, Jangam S, Dunn T, Hayter G. Expanded real-world use reaffirms strong correlation between scanning frequency of flash glucose monitoring and glucose control [Poster 972]. Diabetes. 2019;68(suppl 1).

6. Deshmukh H, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.

7. From baseline 67.2 mg/dL HbA1c across the entire study population.

8. Comparing 2 groups from lowest to highest scan rate (3.6 and 39.5 scans/day).

9. Jangam S, Dunn T, Xu Y, Hayter G, Ajjan R. Flash glucose monitoring improves glycemia in higher-risk patients: a longitudinal, observational study under real-life settings. BMJOpen Diab Res Care 2019;7:e000611. DOl:10.1136/bmjdrc-2018-000611.

Cookie Policy

FreeStyle Libre uses cookies to give you the best possible service. By using our website, you consent to the use of cookies. 

Data protection